id stringlengths 7 9 | image imagewidth (px) 399 3.01k | query stringlengths 12 148 | answers stringlengths 5 329 |
|---|---|---|---|
train_300 | By whom is this document written? | ['Stacey Dixon Calahan'] | |
train_301 | What is the date mentioned? | ['January 21, 1999'] | |
train_302 | To whom is this document addressed? | ['Mr. Larry Ellingson', 'Mr. Ellingson'] | |
train_303 | to which department it belongs to ? | ['DEPARTMENT OF HEALTH AND HUMAN SERVICES', 'department of health and human services.'] | |
train_304 | By whom is this document written? | ['Kunio Iwatani'] | |
train_305 | what is the date of submission? | ['11/18/2002'] | |
train_306 | what is the telephone number (include area code)? | ['847-383-3739'] | |
train_307 | what is the expiration date ? | ['November 30, 2002', 'november 30, 2002'] | |
train_308 | what is the name of the sponsor ? | ['Takeda Pharmaceuticals North America, Inc.', 'Takeda Pharmaceuticals North america , Inc.'] | |
train_309 | what has to be investigated before starting pioglitazone therapy? | ['any macroscopic haematuria'] | |
train_310 | what has been experienced commonly in patients taking actos in combination with insulin? | ['Heart failure', 'heart failure'] | |
train_311 | Which foundation is mentioned in this document? | ['Cleveland Clinic Foundation', 'The Cleveland Clinic Foundation'] | |
train_312 | Under which department , The Cleveland Clinic Foundation operates? | ['Department of Cardiovascular Medicine', 'Department of Cardiovascular Medicine.'] | |
train_313 | What is written in big bold letters at the bottom? | ['DALY 19'] | |
train_314 | Which medicine is used to treat type 2 diabetes mellitus? | ['Actos/Competact'] | |
train_315 | How many cases of bladder cancer from 12506 patients were reported? | ['19 cases'] | |
train_316 | What is the PO Box number? | ['931535'] | |
train_317 | what is the IND mumber (if previously assigned ) ? | ['33,729'] | |
train_318 | what is the date of submission ? | ['11/1/02'] | |
train_319 | what is the Name(s) of drug (include all available names: Trade , Generic, Chemical, Code)? | ['ACTOS (pioglitazone HCI)', 'ACTOS (Pioglitazone HCI)'] | |
train_320 | What is the Tax ID mentioned in this document? | ['34-0714585'] | |
train_321 | what is the form approved : OMB No | ['0910-0014', '0910-0014.'] | |
train_322 | What is the word written in bold on the top of the document? | ['Takeda'] | |
train_323 | What is the date mentioned? | ['19th January 2012'] | |
train_324 | what is the name of pharmaceuticals ? | ['Takeda Pharmaceuticals North America, Inc.', 'TAkeda pharmaceuticals North America ,INc.'] | |
train_325 | to whom this letter is written ? | ['Janet L. Haskins', 'janet L. haskins', 'Ms. Haskins'] | |
train_326 | When did Regulatory affairs department receive this letter? | ['JUN 16 2003'] | |
train_327 | To whom was this letter written? | ['Healthcare Professional'] | |
train_328 | What is the fifth point? | ['WAC and AWP generally;', 'WAC AND AWP generally;'] | |
train_329 | Education grants regarding which products? | ['TPNA', 'TPNA products'] | |
train_330 | What is the date this document was last printed? | ['11/30/2012', '11/30/2012 4:28:00 AM'] | |
train_331 | To whom a copy of cover letter has to be sent ? | ['Ms. Jens Weber'] | |
train_332 | Which reimbursement for TPNA pharmaceutical products is generally given? | ['Medicare and Medicaid'] | |
train_333 | What is the designation of Alfonso T. Perez, M.D.? | ['Vice President, Clinical Research'] | |
train_334 | By whom was this agreement Agreed and Accepted? | ['Richard A. Rudick, M.D.', 'Richard A. Rudick, M.D. Chairman, Division of Clinical Research', 'Richard A. Rudick'] | |
train_335 | What is the full form of FAR? | ['Federal Acquisitions Regulation'] | |
train_336 | What is the number written above TAK-INDNDA-01577086? | ['425'] | |
train_337 | What is the contact number of Ms. Jena Weber, Regulatory Project Manager? | ['301-827-6422'] | |
train_338 | What is the full form of ODE? | ['Office of Drug Evaluation'] | |
train_339 | What is written above Page 2 on the top? | ['IND 33, 729'] | |
train_340 | what is the unit mentioned in the letter ? | ['7200'] | |
train_341 | Name of the first person in the To list? | ['PJ Daniels', 'pj Daniels'] | |
train_342 | from whose desk this letter is written ? | ['Timothy J. Gumbleton', 'timothy J Gumbleton'] | |
train_343 | Whose letter's copy is attached? | ['DR. Mitchell', 'Dr. Mitchell'] | |
train_344 | what is the date mentioned ? | ['February 6, 1996', 'february 6 , 1996'] | |
train_345 | to whom this letter is written ? | ['Dr. K. KItazawa', 'Dr . k. Kitazawa'] | |
train_346 | this letter is written by whom ? | ['T. Suzuki', 'Tsuyoshi Suzuki , M S .'] | |
train_347 | Which laboratory is T. Suzuki associated with ? | ['Drug Safety Research Laboratories', 'drug safety research laboratories .'] | |
train_348 | what is the date mentioned in the letter | ['August 8, 2002', 'august 8 , 2002'] | |
train_349 | What is the name of the industry given here? | ['Takeda chemical industries, LTD .', 'TAKEDA CHEMICAL INDUSTRIES, LTD.'] | |
train_350 | to whom this letter is written ? | ['Dr. Claire Thom', 'Dr. Thom'] | |
train_351 | what is the name mentioned in CC | ['Mr. S. Hamanaka', 'Mr . S . Hamanaka'] | |
train_352 | Who sent this letter? | ['Katsuhisa Saito', 'katsuhisa saito'] | |
train_353 | what is Ref: code mentioned ? | ['TPNA-TS-020808'] | |
train_354 | What is the venue mentioned in the document? | ['TPNA, Chicago'] | |
train_355 | What is the date mentioned in the document? | ['Monday, 12 and Tuesday, 13 August 2002'] | |
train_356 | what is the fax number mentioned in the letter at the top? | ['06 6204 2244'] | |
train_357 | what is the date and time mentioned ? | ['10/27/93 09:36:07'] | |
train_358 | what is mentioned in the subject ? | ['Pioglitazone statement', 'pioglitazone statement'] | |
train_359 | To whom this email was send? | ['PETER J. DANIELS', 'PJ DANIEL--PW17PO PETER J. DANIELS'] | |
train_360 | what is the date mentioned in the forwarding note ? | ['10/26/93', '10/26/93 15:44'] | |
train_361 | what is the time mentioned in the forwarding note ? | ['15:44'] | |
train_362 | To whom this email was forwaded? | ['RUPPEL, PATRICIA', 'PLRUPPEL--RCC1 RUPPEL, PATRICIA'] | |
train_363 | what is the name of the company | ['THE UPJOHN COMPANY'] | |
train_364 | what is the date and year mentioned ? | ['September 21, 1993', 'september 21 , 1993'] | |
train_365 | Which company is mentioned in the letterhead? | ['THE UPJOHN COMPANY'] | |
train_366 | in which country the upjohn company is located ? | ['U.S.A', 'USA'] | |
train_367 | what is the fax mentioned ? | ['06 6204 2244'] | |
train_368 | what is year date and time mentioned? | ['2002 08/08 21:49'] | |
train_369 | what is the name of the division ? | ['TAKEDA DEVELOP DIVISION', 'Takeda Develop division'] | |
train_370 | to whom they can ask directly to disclose the details of "promotion study"? | ['FDA'] | |
train_371 | what is the date mentioned in the letter | ['8 January 2003', '8 january 2003'] | |
train_372 | To whom this letter is addressed? | ['MPDRAP I Leader'] | |
train_373 | what is mentioned in the CC? | ['CEOs and General Managers of Pharmaceutical Units', 'CEOs and general managers of pharmaceutical units'] | |
train_374 | combination therapy in the us market accounts for how much % of total actos sales . | ['64', '64%'] | |
train_375 | What is the due date to evaluate data from actos 507? | ['August 5'] | |
train_376 | who is the lead responsibility for developing additional monitoring plan for actos 508 | ['Amy Hagaman', 'Amy hagaman'] | |
train_377 | what is the due date for "draft justification for actos 508" ? | ['August 12', 'august 12'] | |
train_378 | when was this last updated ? | ['August 1, 2002', 'august 1, 2002'] | |
train_379 | Which is the core organization of Takeda pharmaceutical Company? | ['Pharmaceutical development Division', 'Pharmaceutical Development Division'] | |
train_380 | Who made the opening remarks ? | ['Dr. Kitazawa'] | |
train_381 | When is the clinical expert meeting scheduled? | ['for October 1 and 2.', 'October 1 and 2'] | |
train_382 | what is the date mentioned in the given information ? | ['20 April 2006', '20 april 2006'] | |
train_383 | What is the meeting time mentioned here? | ['4:00pm - 5:00pm'] | |
train_384 | what is the place mentioned ? | ['Meeting Room 403', 'meeting room 403'] | |
train_385 | Why was it suggested to prepare non-clinical "White paper"? | ['to address the bladder issue', 'to address the bladder issue.'] | |
train_386 | who will forward the article regarding rosiglitazone and non clinical bladder data to andy ? | ['Mondira'] | |
train_387 | What date is the meeting scheduled to develop the overall structure of the document? | ['in early May'] | |
train_388 | Who presented an outline of the Cohen hypothesis? | ['Philip Collett'] | |
train_389 | What is significant in the development of calculi? | ['Raising the pH of male rat urine above 6.5'] | |
train_390 | What is the correlation observed in cohen's paper? | ['0.61'] | |
train_391 | Why didn't rats eliminate calculi as humans do? | ['Because rats are quadropeds', 'Because rats are quadropeds.'] | |
train_392 | What is the fullform of MAA? | ['Marketing Authorization Application'] | |
train_393 | Which forum is mentioned in this document? | ['Takeda Global Risk Management Forum', 'Takeda Global Risk Management Forum/March 22, 2004'] | |
train_394 | What is the issued date of this document? | ['august 13, 2002', 'August 13, 2002'] | |
train_395 | Who is the Director of Nonclinical Safety and Efficacy? | ['David baron', 'David Baron'] | |
train_396 | What is the duration of daily dosing? | ['32-weeks', '32-weeks after BBN.'] | |
train_397 | Who updated the CEO on August 6? | ['Mr. Saito'] | |
train_398 | By when should TPNA send outline of response to TCI ? | ['August 19', 'by August 19'] | |
train_399 | When will Mr. Saito present outline to CEO? | ['August 20', 'on August 20'] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.